A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Group Sequential, Phase 3 Study to Evaluate the Efficacy and Safety of Rilzabrutinib in Patients Aged 10 to 65 Years With Sickle-cell Disease
Latest Information Update: 02 Jun 2025
At a glance
- Drugs Rilzabrutinib (Primary)
- Indications Sickle cell anaemia
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms LIBRA
- Sponsors Sanofi
Most Recent Events
- 23 May 2025 New trial record